{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:38:50Z","timestamp":1793342330976,"version":"4.5.0"},"reference-count":76,"publisher":"American Association for Cancer Research (AACR)","issue":"3","funder":[{"DOI":"10.13039\/501100003653","name":"National Institute of Health","doi-asserted-by":"publisher","award":["2RO1CA129933"],"award-info":[{"award-number":["2RO1CA129933"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003653","name":"National Institute of Health","doi-asserted-by":"publisher","award":["2U01EB012493"],"award-info":[{"award-number":["2U01EB012493"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003653","name":"National Institute of Health","doi-asserted-by":"publisher","award":["5U01EB012493"],"award-info":[{"award-number":["5U01EB012493"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003653","name":"National Institute of Health","doi-asserted-by":"publisher","award":["5P41EB002503"],"award-info":[{"award-number":["5P41EB002503"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ESSCO Breast Cancer Research Fund","id":[{"id":"https:\/\/ror.org\/03xzf6x18","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001767","name":"National Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001767","id-type":"DOI","asserted-by":"publisher"}]},{"name":"IBM funding"},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["PHY-1549535"],"award-info":[{"award-number":["PHY-1549535"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005979","name":"Lustgarten Foundation","doi-asserted-by":"publisher","award":["2015-002"],"award-info":[{"award-number":["2015-002"]}],"id":[{"id":"10.13039\/100005979","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Circulating tumor cells (CTC) are shed by cancer into the bloodstream, where a viable subset overcomes oxidative stress to initiate metastasis. We show that single CTCs from patients with melanoma coordinately upregulate lipogenesis and iron homeostasis pathways. These are correlated with both intrinsic and acquired resistance to BRAF inhibitors across clonal cultures of BRAF-mutant CTCs. The lipogenesis regulator SREBP2 directly induces transcription of the iron carrier Transferrin (TF), reducing intracellular iron pools, reactive oxygen species, and lipid peroxidation, thereby conferring resistance to inducers of ferroptosis. Knockdown of endogenous TF impairs tumor formation by melanoma CTCs, and their tumorigenic defects are partially rescued by the lipophilic antioxidants ferrostatin-1 and vitamin E. In a prospective melanoma cohort, presence of CTCs with high lipogenic and iron metabolic RNA signatures is correlated with adverse clinical outcome, irrespective of treatment regimen. Thus, SREBP2-driven iron homeostatic pathways contribute to cancer progression, drug resistance, and metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Through single-cell analysis of primary and cultured melanoma CTCs, we have uncovered intrinsic cancer cell heterogeneity within lipogenic and iron homeostatic pathways that modulates resistance to BRAF inhibitors and to ferroptosis inducers. Activation of these pathways within CTCs is correlated with adverse clinical outcome, pointing to therapeutic opportunities.<\/jats:p>\n                    <jats:p>This article is highlighted in the In This Issue feature, p. 521<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-19-1500","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T14:45:14Z","timestamp":1605624314000},"page":"678-695","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":232,"title":["The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis"],"prefix":"10.1158","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9671-0116","authenticated-orcid":false,"given":"Xin","family":"Hong","sequence":"first","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7395-9939","authenticated-orcid":false,"given":"Whijae","family":"Roh","sequence":"additional","affiliation":[{"name":"2Broad Institute of Harvard and MIT, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."},{"name":"3Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6578-0373","authenticated-orcid":false,"given":"Keith H.K.","family":"Wong","sequence":"additional","affiliation":[{"name":"4Center for Engineering in Medicine, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts."},{"name":"5Shriners Hospitals for Children, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5657-9849","authenticated-orcid":false,"given":"Ben S.","family":"Wittner","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongshan","family":"Guo","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taronish D.","family":"Dubash","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Sade-Feldman","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."},{"name":"2Broad Institute of Harvard and MIT, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wesley","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0361-3374","authenticated-orcid":false,"given":"Elad","family":"Horwitz","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7522-6173","authenticated-orcid":false,"given":"Genevieve M.","family":"Boland","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."},{"name":"6Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieuwke L.","family":"Marvin","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Bonesteel","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7905-2078","authenticated-orcid":false,"given":"Chenyue","family":"Lu","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9414-300X","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Aguet","sequence":"additional","affiliation":[{"name":"2Broad Institute of Harvard and MIT, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Burr","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8285-0057","authenticated-orcid":false,"given":"Samuel S.","family":"Freeman","sequence":"additional","affiliation":[{"name":"2Broad Institute of Harvard and MIT, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7872-5074","authenticated-orcid":false,"given":"Laxmi","family":"Parida","sequence":"additional","affiliation":[{"name":"9IBM Research, Yorktown Heights, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Calhoun","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."},{"name":"4Center for Engineering in Medicine, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle K.","family":"Jewett","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."},{"name":"4Center for Engineering in Medicine, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0141-8308","authenticated-orcid":false,"given":"Linda T.","family":"Nieman","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Hacohen","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."},{"name":"2Broad Institute of Harvard and MIT, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders M.","family":"N\u00e4\u00e4r","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3261-2322","authenticated-orcid":false,"given":"David T.","family":"Ting","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."},{"name":"3Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Toner","sequence":"additional","affiliation":[{"name":"4Center for Engineering in Medicine, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts."},{"name":"5Shriners Hospitals for Children, Boston, Massachusetts."},{"name":"6Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Stott","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."},{"name":"3Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":false,"given":"Gad","family":"Getz","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."},{"name":"2Broad Institute of Harvard and MIT, Cambridge, Massachusetts."},{"name":"7Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyamala","family":"Maheswaran","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."},{"name":"6Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Haber","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts."},{"name":"3Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts."},{"name":"8Howard Hughes Medical Institute, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"key":"2022060622525096000_bib1","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"2022060622525096000_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"2022060622525096000_bib3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"2022060622525096000_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2022060622525096000_bib5","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"2022060622525096000_bib6","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"2022060622525096000_bib7","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2022060622525096000_bib8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2022060622525096000_bib9","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2022060622525096000_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"2022060622525096000_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"2022060622525096000_bib12","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2022060622525096000_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cell.2019.08.032","article-title":"UVB-induced tumor heterogeneity diminishes immune response in melanoma","volume":"179","author":"Wolf","year":"2019","journal-title":"Cell"},{"key":"2022060622525096000_bib14","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2017.07.025","article-title":"Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient","volume":"170","author":"Jimenez-Sanchez","year":"2017","journal-title":"Cell"},{"key":"2022060622525096000_bib15","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022060622525096000_bib16","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022060622525096000_bib17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature15726","article-title":"Oxidative stress inhibits distant metastasis by human melanoma cells","volume":"527","author":"Piskounova","year":"2015","journal-title":"Nature"},{"key":"2022060622525096000_bib18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1083\/jcb.201010021","article-title":"Circulating tumor cells: approaches to isolation and characterization","volume":"192","author":"Yu","year":"2011","journal-title":"J Cell Biol"},{"key":"2022060622525096000_bib19","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","article-title":"Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases","volume":"10","author":"Allard","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2022060622525096000_bib20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N Engl J Med"},{"key":"2022060622525096000_bib21","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.celrep.2014.03.039","article-title":"Isolation and molecular characterization of circulating melanoma cells","volume":"7","author":"Luo","year":"2014","journal-title":"Cell Rep"},{"key":"2022060622525096000_bib22","doi-asserted-by":"crossref","first-page":"179ra47","DOI":"10.1126\/scitranslmed.3005616","article-title":"Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells","volume":"5","author":"Ozkumur","year":"2013","journal-title":"Sci Transl Med"},{"key":"2022060622525096000_bib23","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nprot.2014.044","article-title":"Microfluidic, marker-free isolation of circulating tumor cells from blood samples","volume":"9","author":"Karabacak","year":"2014","journal-title":"Nat Protoc"},{"key":"2022060622525096000_bib24","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1073\/pnas.1719264115","article-title":"Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy","volume":"115","author":"Hong","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060622525096000_bib25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1126\/science.1253533","article-title":"Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility","volume":"345","author":"Yu","year":"2014","journal-title":"Science"},{"key":"2022060622525096000_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41698-019-0090-5","article-title":"Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer","volume":"3","author":"Medford","year":"2019","journal-title":"NPJ Precis Oncol"},{"key":"2022060622525096000_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature19328","article-title":"HER2 expression identifies dynamic functional states within circulating breast cancer cells","volume":"537","author":"Jordan","year":"2016","journal-title":"Nature"},{"key":"2022060622525096000_bib28","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"key":"2022060622525096000_bib29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"2022060622525096000_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"2022060622525096000_bib31","doi-asserted-by":"crossref","first-page":"8288","DOI":"10.1128\/MCB.24.18.8288-8300.2004","article-title":"Selective coactivator interactions in gene activation by SREBP-1a and -1c","volume":"24","author":"Toth","year":"2004","journal-title":"Mol Cell Biol"},{"key":"2022060622525096000_bib32","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41588-017-0027-2","article-title":"An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer","volume":"50","author":"Chen","year":"2018","journal-title":"Nat Genet"},{"key":"2022060622525096000_bib33","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrendo.2017.91","article-title":"SREBP-regulated lipid metabolism: convergent physiology-divergent pathophysiology","volume":"13","author":"Shimano","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"2022060622525096000_bib34","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/onc.2015.179","article-title":"Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP","volume":"35","author":"Ricoult","year":"2016","journal-title":"Oncogene"},{"key":"2022060622525096000_bib35","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.cell.2014.08.009","article-title":"Determination and inference of eukaryotic transcription factor sequence specificity","volume":"158","author":"Weirauch","year":"2014","journal-title":"Cell"},{"key":"2022060622525096000_bib36","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1155\/MBD.1994.161","article-title":"Transferrin: from inorganic biochemistry to medicine","volume":"1","author":"Messori","year":"1994","journal-title":"Met Based Drugs"},{"key":"2022060622525096000_bib37","first-page":"916","article-title":"Transferrin receptor 1 in cancer: a new sight for cancer therapy","volume":"8","author":"Shen","year":"2018","journal-title":"Am J Cancer Res"},{"key":"2022060622525096000_bib38","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1073\/pnas.82.19.6706","article-title":"Transferrin gene expression visualized in oligodendrocytes of the rat brain by using in situ hybridization and immunohistochemistry","volume":"82","author":"Bloch","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060622525096000_bib39","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/hep.510270220","article-title":"Transferrin and transferrin receptor gene expression and iron uptake in hepatocellular carcinoma in the rat","volume":"27","author":"Pascale","year":"1998","journal-title":"Hepatology"},{"key":"2022060622525096000_bib40","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","article-title":"Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis","volume":"158","author":"Aceto","year":"2014","journal-title":"Cell"},{"key":"2022060622525096000_bib41","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1126\/science.aab0917","article-title":"RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance","volume":"349","author":"Miyamoto","year":"2015","journal-title":"Science"},{"key":"2022060622525096000_bib42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0891-5849(02)00842-0","article-title":"Ferritin, iron homeostasis, and oxidative damage","volume":"33","author":"Arosio","year":"2002","journal-title":"Free Radic Biol Med"},{"key":"2022060622525096000_bib43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","article-title":"Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease","volume":"171","author":"Stockwell","year":"2017","journal-title":"Cell"},{"key":"2022060622525096000_bib44","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","article-title":"Targeting ferroptosis to iron out cancer","volume":"35","author":"Hassannia","year":"2019","journal-title":"Cancer Cell"},{"key":"2022060622525096000_bib45","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.chembiol.2008.02.010","article-title":"Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells","volume":"15","author":"Yang","year":"2008","journal-title":"Chem Biol"},{"key":"2022060622525096000_bib46","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature24297","article-title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"key":"2022060622525096000_bib47","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nature23007","article-title":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","volume":"547","author":"Viswanathan","year":"2017","journal-title":"Nature"},{"key":"2022060622525096000_bib48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrc3498","article-title":"Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?","volume":"13","author":"Holzel","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"2022060622525096000_bib49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1101\/sqb.2016.81.031120","article-title":"Single-cell analysis of circulating tumor cells as a window into tumor heterogeneity","volume":"81","author":"Miyamoto","year":"2016","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"2022060622525096000_bib50","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.3892\/ol.2016.4988","article-title":"SREBP-1 is an independent prognostic marker and promotes invasion and migration in breast cancer","volume":"12","author":"Bao","year":"2016","journal-title":"Oncol Lett"},{"key":"2022060622525096000_bib51","doi-asserted-by":"crossref","first-page":"ra82","DOI":"10.1126\/scisignal.2000446","article-title":"EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy","volume":"2","author":"Guo","year":"2009","journal-title":"Sci Signal"},{"key":"2022060622525096000_bib52","doi-asserted-by":"crossref","first-page":"e00265","DOI":"10.1128\/MCB.00265-17","article-title":"RNF20 suppresses tumorigenesis by inhibiting the SREBP1c-PTTG1 axis in kidney cancer","volume":"37","author":"Lee","year":"2017","journal-title":"Mol Cell Biol"},{"key":"2022060622525096000_bib53","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1038\/s41467-018-04664-0","article-title":"Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy","volume":"9","author":"Talebi","year":"2018","journal-title":"Nat Commun"},{"key":"2022060622525096000_bib54","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2174\/13816128113199990486","article-title":"Targeting SREBP-1-driven lipid metabolism to treat cancer","volume":"20","author":"Guo","year":"2014","journal-title":"Curr Pharm Des"},{"key":"2022060622525096000_bib55","doi-asserted-by":"crossref","first-page":"12027","DOI":"10.1073\/pnas.1534923100","article-title":"Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes","volume":"100","author":"Horton","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060622525096000_bib56","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","article-title":"CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy","volume":"569","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"2022060622525096000_bib57","doi-asserted-by":"crossref","first-page":"6376","DOI":"10.18632\/oncotarget.14093","article-title":"Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism","volume":"8","author":"Rychtarcikova","year":"2017","journal-title":"Oncotarget"},{"key":"2022060622525096000_bib58","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.molcel.2015.06.011","article-title":"Glutaminolysis and transferrin regulate ferroptosis","volume":"59","author":"Gao","year":"2015","journal-title":"Mol Cell"},{"key":"2022060622525096000_bib59","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ccell.2018.05.001","article-title":"Cancer cells co-opt the neuronal redox-sensing channel TRPA1 to promote oxidative-stress tolerance","volume":"33","author":"Takahashi","year":"2018","journal-title":"Cancer Cell"},{"key":"2022060622525096000_bib60","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","article-title":"Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress","volume":"33","author":"Tsoi","year":"2018","journal-title":"Cancer Cell"},{"key":"2022060622525096000_bib61","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1126\/science.aaa5004","article-title":"Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH","volume":"350","author":"Yun","year":"2015","journal-title":"Science"},{"key":"2022060622525096000_bib62","doi-asserted-by":"crossref","first-page":"14344","DOI":"10.1038\/ncomms14344","article-title":"Expression of beta-globin by cancer cells promotes cell survival during blood-borne dissemination","volume":"8","author":"Zheng","year":"2017","journal-title":"Nat Commun"},{"key":"2022060622525096000_bib63","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1126\/science.275.5306.1649","article-title":"Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts","volume":"275","author":"Irani","year":"1997","journal-title":"Science"},{"key":"2022060622525096000_bib64","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/carcin\/bgn167","article-title":"Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells","volume":"29","author":"Chan","year":"2008","journal-title":"Carcinogenesis"},{"key":"2022060622525096000_bib65","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/0008-5472.CAN-07-5259","article-title":"Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype","volume":"68","author":"Kumar","year":"2008","journal-title":"Cancer Res"},{"key":"2022060622525096000_bib66","doi-asserted-by":"crossref","first-page":"308re8","DOI":"10.1126\/scitranslmed.aad3740","article-title":"Antioxidants can increase melanoma metastasis in mice","volume":"7","author":"Le Gal","year":"2015","journal-title":"Sci Transl Med"},{"key":"2022060622525096000_bib67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41586-020-2623-z","article-title":"Lymph protects metastasizing melanoma cells from ferroptosis","volume":"585","author":"Ubellacker","year":"2020","journal-title":"Nature"},{"key":"2022060622525096000_bib68","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"2022060622525096000_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-017-4246-0","article-title":"The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis","volume":"164","author":"Liu","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"2022060622525096000_bib70","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s12094-018-1992-3","article-title":"Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies","volume":"21","author":"Abdel-Rahman","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"2022060622525096000_bib71","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.3748\/wjg.v20.i7.1858","article-title":"Statins and the risk of colorectal cancer: an updated systematic review and meta-analysis of 40 studies","volume":"20","author":"Lytras","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2022060622525096000_bib72","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1200\/JCO.2012.44.6831","article-title":"Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection","volume":"31","author":"Tsan","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022060622525096000_bib73","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00404-017-4533-3","article-title":"Exploring association between statin use and breast cancer risk: an updated meta-analysis","volume":"296","author":"Islam","year":"2017","journal-title":"Arch Gynecol Obstet"},{"key":"2022060622525096000_bib74","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41467-017-01705-y","article-title":"Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells","volume":"8","author":"Wong","year":"2017","journal-title":"Nat Commun"},{"key":"2022060622525096000_bib75","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.cell.2006.01.040","article-title":"A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen","volume":"124","author":"Moffat","year":"2006","journal-title":"Cell"},{"key":"2022060622525096000_bib76","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cell.2018.12.034","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"176","author":"Sade-Feldman","year":"2019","journal-title":"Cell"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/11\/3\/678\/3040694\/678.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/11\/3\/678\/3040694\/678.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T18:53:51Z","timestamp":1654541631000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/11\/3\/678\/3309\/The-Lipogenic-Regulator-SREBP2-Induces-Transferrin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,2]]},"published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-19-1500","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.22536574","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536595","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536583","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536592","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536601","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536592.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536586.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536583.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536601.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536577.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6548173","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536589","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536577","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536598","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536586","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536574.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536595.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536598.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6548173.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22536589.v1","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}